To the full analysis
Novartis stock: growth
NOVN.SWNovartis reported $57.13B in revenue for fiscal 2025, up 10.4% on the prior year, up 2.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
2.6%
per year from 2006 to 2025, per share 3.6%
Earnings (Annual rate)
3.8%
per year from 2006 to 2025, per share 4.9%
Free cash flow (Annual rate)
5.7%
per year from 2006 to 2025, per share 6.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.7% | 1.3% | 2.6% |
| Revenue per share | 6.1% | 3.5% | 3.6% |
| Earnings | 12.7% | −1.9% | 3.8% |
| Earnings per share | 16.3% | 0.2% | 4.9% |
| Free cash flow | 10.7% | 8.6% | 5.7% |
| Free cash flow per share | 14.4% | 11.0% | 6.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $35.11B | $7.18B | $6.39B |
| 2007 | $38.95B | $11.95B | $6.08B |
| 2008 | $42.58B | $8.2B | $7.45B |
| 2009 | $45.1B | $8.4B | $9.46B |
| 2010 | $51.56B | $9.79B | $11.84B |
| 2011 | $59.38B | $8.94B | $11.92B |
| 2012 | $51.97B | $9.27B | $10.89B |
| 2013 | $52.72B | $9.18B | $9.4B |
| 2014 | $53.63B | $10.21B | $10.19B |
| 2015 | $50.39B | $17.78B | $8.05B |
| 2016 | $49.44B | $6.71B | $8.6B |
| 2017 | $43.4B | $7.7B | $9.88B |
| 2018 | $46.1B | $12.61B | $10.92B |
| 2019 | $48.68B | $11.73B | $11.37B |
| 2020 | $49.9B | $8.07B | $11.07B |
| 2021 | $43.97B | $24.02B | $12.1B |
| 2022 | $43.46B | $6.96B | $11.57B |
| 2023 | $46.66B | $14.85B | $11.71B |
| 2024 | $51.72B | $11.94B | $13.81B |
| 2025 | $57.13B | $14.65B | $18.43B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 25 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.